China Issues First Standard for AI-Driven Brain-Computer Interface Devices

China's National Medical Products Administration (NMPA) has approved a landmark industry standard regulating brain-computer interface (BCI) medical devices that utilize artificial intelligence to process electroencephalogram (EEG) data. Announced on September 14, the measure is China's third BCI-related medical standard and is identified by state media as the world's first product standard addressing AI-based EEG signal processing. Set to take effect on September 1, 2027, the standard defines dataset quality requirements and evaluation methodologies across the research, manufacturing, and quality assurance phases of device development.

BCI technology represents a critical intersection of neuroscience, medical hardware, and advanced machine learning. Because raw neural signals are noisy and subject to significant variability, the integrity of underlying training and validation datasets directly impacts clinical efficacy and patient safety. By formalizing technical benchmarks for EEG data quality, regulatory authorities are establishing standardized criteria for pre-clinical assessment and device review, which could reduce uncertainty for commercial developers and lower compliance hurdles for cross-disciplinary medical technology.

China's drug and medical device regulator has approved a new national standard governing the use of artificial intelligence in brain-computer interface (BCI) medical hardware, marking an early regulatory step to codify technical requirements for neural data processing. The National Medical Products Administration (NMPA) approved the document on September 14, according to a report by Xinhua News Agency. The measure represents China's third specialized medical device standard for brain-computer interfaces and has been characterized by state media as the world's first product standard dedicated to BCI devices that deploy artificial intelligence algorithms to interpret electroencephalogram (EEG) signals. The standard is scheduled to take effect formally on September 1, 2027. Technically, the standard establishes specific quality benchmarks and evaluation methodologies for EEG datasets used in conjunction with machine-learning algorithms. Its scope covers the entire product development lifecycle, applying to datasets utilized in research and development, manufacturing, and post-market quality control for devices where AI models perform post-processing on captured neural electrical signals. Brain-computer interfaces translate electrical activity from the brain into actionable commands or diagnostic data. In non-invasive and semi-invasive systems, EEG signals are notoriously prone to interference from muscle movement, electrical noise, and anatomical differences across subjects. Consequently, the performance and reliability of AI models used to filter, decode, and interpret these signals depend heavily on the quality, labeling, and consistency of the training and validation data. By codifying data quality metrics, Chinese regulators aim to resolve evaluation ambiguities during clinical trials and regulatory reviews. The nearly three-year gap before the standard takes legal effect in late 2027 gives medical device manufacturers and research institutions an extended transition window to audit their data collection protocols, update algorithm pipelines, and align proprietary testing frameworks with state specifications.